SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending as traders debate the stock's post-earnings volatility, with many attributing the price decline to market maker manipulation and option-killing tactics despite strong financial results and an expanding AI backlog. While some investors view the pullback as a buying opportunity, others express frustration over the stock's inability to maintain gains or criticize its debt and cash flow position.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo shares are under pressure as traders react to the company launching a new 1 billion dollar at-the-market equity offering program, fueling widespread concerns about shareholder dilution. While some investors view the price decline as a buying opportunity, citing the company's long-term potential in AI-driven energy demand, many in the community are expressing frustration over the persistent dilution and speculative nature of the stock.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power shares are seeing significant volatility as traders react to a wide revenue miss and a concurrent announcement of a new at-the-market equity offering. While some participants view the pullback as a buying opportunity based on long-term nuclear energy demand, others are expressing frustration over the company's limited commercial progress and continued capital raising efforts.

Alliance Entertainment Holding Corp. engages in the distribution of music, movies, and consumer electronics. It distributes its physical media, entertainment products, hardware, and accessories through an established multi-channel strategy. The company was founded in 1990 and is headquartered in Plantation, FL.

Alliance Entertainment Holding Corporation - Ordinary Shares - Class A

AENT is trending as traders speculate on potential stock price recovery and discuss its low float status. Investors are debating the company's long-term prospects, focusing on its role in physical media distribution and collectibles, despite frustration over recent volatility.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is trending as traders debate the sustainability of its recent rally, with many expressing skepticism regarding the stock's valuation and citing concerns over insider selling and large bond offerings. While bulls point to robust demand for AI-optimized servers and positive analyst coverage, bears suspect price manipulation and warn of a potential pullback.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as traders speculate on the timing and results of upcoming maintenance study data for its obesity candidate, VK2735. While some investors remain optimistic about potential buyout interest and the drug's efficacy, others express frustration over the company's communication style and lack of immediate news.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is trending due to a strong fiscal third-quarter earnings report that featured triple-digit revenue growth and significantly raised full-year guidance, fueled by accelerating demand for AI data center and grid infrastructure. While some traders express caution over secondary equity offerings and lock-up expirations, others remain bullish on the company's massive order backlog and critical role in the power infrastructure buildout.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending as traders debate the company's valuation and potential turnaround, with discussion focused on heavy insider buying and speculation regarding the possible sale of the STAR debit network. While some investors view the current price as a long-term value opportunity, others express significant frustration over management execution and weak performance, maintaining a bearish outlook until there is clear evidence of a recovery.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake shares are facing significant downward pressure following the release of Phase 3 IZAR-1 trial data, which investors feel failed to demonstrate the expected best-in-class efficacy for sonelokimab in psoriatic arthritis, compounded by investor frustration over a new mixed shelf filing that suggests potential future dilution.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following a record-breaking second-quarter earnings report that exceeded analyst expectations and led to positive analyst price target revisions. While some traders express frustration over macro headwinds like geopolitical tensions and interest rate volatility, many remain bullish on the company's long-term growth potential and undervalued position relative to its fintech peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?

Key PointsIt's a cancer medication with immense potential...

Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage

Equity

CEO Mark Goldsmith said discussions with insurers gave the company confidence that they understand the drug’s clinical value.

When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.read more...

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer  

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold.

Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.read more...

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regimens.


Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an annualized basis producing an average annual return of 49.25%. Currently, Revolution Medicines has a marketread more...

RVMD Stock Stays Flat Despite FDA Nod For $39,800-A-Month Pancreatic Cancer Pill — Is Drug Price Overshadowing Approval?

The Food and Drug Administration (FDA) cleared the once-daily tablet, Rasonque, for certain adults with metastatic pancreatic adenocarcinoma. 

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs chemotherapy.read more...

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Bearish Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$2.41	--	--	N/A
Q2 '26	-$2.04	-$3.06	-49.81%	MISSED
Q1 '26	-$1.84	-$2.29	-24.75%	MISSED
Q4 '25	-$1.58	-$1.86	-17.63%	MISSED
Q3 '25	-$1.42	-$1.61	-13.29%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

RVMD Earnings

Upcoming Earnings: Q3 '26

Historical Earnings